Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™. Orphan drug designation is given to drugs and biologics being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S. Orphan […]
News
Adaptive Phage Therapeutics Receives Orphan Drug Designation
APT named 2020 Emerging Life Science Company of the Year
The Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners of its 32nd Annual Industry Awards. Due to COVID-19, the association pivoted to a virtual live broadcast to announce winners for the first time in the organization’s history.
APT Receives DoD Award for Development of COVID-19 Vaccine
GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate […]
Mayo Clinic as Lead Investor in Convertible Note Financing
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.
APT featured in Netflix Series
APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe.
APT and John Haverty featured in the Boston Globe
For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like Haverty’s], and he happened across Maryland-based Adaptive Phage Therapeutics.
Collaboration with Mayo Clinic
GAITHERSBURG, Md.–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid identification […]
Infectious disease and the need for more options
By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.
APT featured in Dutch Broadcast
Adaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections. The discussion regarding APT begins at the 35 minute mark and features John Haverty (a patient helped by APT).
A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty
“Never Give Up on Your Life” – John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years. He wasn’t able to walk and put both feet on the ground for over 10 year. Doctors at Mayo Clinic were about […]